癌症治疗药市场:癌症类型，疗法，终端用户，各地区，2024年～2031年

癌症药物市场评估，2024-2031

癌症治疗市场已达到一个重要里程碑，到 2023 年将达到 1,499.2 亿美元。这项成就的实现有多种因素，包括加强研发力度、加强製药公司之间的合作以及加强对医疗保健领域的投资。预计2024年至2031年期间，该市场将经历一个充满希望的发展轨迹，复合年增长率预计为14.6%。预计到 2031 年将飙升至惊人的 4,914.1 亿美元，反映了该行业内的持续成长势头和不断变化的动态。

这一增长得益于全球癌症发病率上升、政府促进早期检测的努力、癌症研究的稳步增长以及技术进步等因素，所有这些我们都为治疗药物的进步做出了贡献。

癌症药物市场定义/概述

癌症药物包括针对癌细胞变化以抑制肿瘤生长的治疗方法，例如放射疗法、化学疗法和手术。这些治疗的应用根据癌症的类型和阶段而有所不同，并且正在进行研究和临床试验来探索免疫治疗、标靶治疗、荷尔蒙治疗和干细胞移植等治疗方法。市场区隔是根据癌症类型和最终用户进行的，市场受到全球癌症发病率上升的推动，预计到 2031 年，癌症发病率将翻一番，尤其是在亚洲、欧洲和美洲。

製药公司之间不断加强的合作和研究工作进一步推动了市场成长。市场扩张是由政府提高癌症意识和个人化医疗需求的措施所推动的。

推动癌症治疗药物市场成长的因素有哪些？

全球癌症盛行率不断上升，特别是在亚洲、欧洲和美洲等地区，推动了对有效治疗方案的需求。癌症患者数量的增加需要先进的治疗药物，促使市场扩张。癌症治疗的创新很大程度上是由肿瘤学领域的研究和开发的增加所推动的。透过研究和临床试验不断探索推动新药和治疗方法的发现，从而以更有效的解决方案丰富市场。

此外，製药公司、研究机构和各个利害关係人之间的合作也促进了创新和癌症药物开发的加速。这种伙伴关係有利于资源汇集和知识共享，从而加强管道并更快地将新药推向市场。此外，政府旨在提高癌症意识、促进早期检测和提供研究资金的措施也促进了市场成长。

癌症患者可用的治疗选择的扩大是由基因组测试和技术创新的进步推动的，也是由针对每个患者的情况量身定制的个性化医疗不断增长的需求推动的。这些因素的汇合，为抗癌药物市场的持续发展和扩大创造了良好的环境。

哪些因素导致癌症治疗药物市场销售大幅下滑？

由于重磅药物的专利到期而导致仿製药的出现增加了竞争并降低了品牌抗癌药物的价格。竞争的加剧给製药公司带来了挑战，并导致企业利润下降。此外，新抗癌药物的取得受到药物审批和报销的严格监管要求以及医疗保健支付者的定价压力的限制。监管审批的延迟和报销政策的变化可能会进一步限制抗癌药物的采用并对销售产生负面影响。

品牌抗癌药物（尤其是专利保护已过期的药物）引进仿製药，导致原厂药公司的价格和销售大幅下降。治疗范式也受到癌症研究进展以及医疗保健提供者对免疫疗法和标靶疗法等新疗法偏好变化的影响。这种转变可能会减少传统化疗的使用，并进一步影响传统抗癌药物的销售。经济衰退、医疗保健支出变化、报销波动等经济因素，以及治疗依从性和可及性方面的挑战，使製药公司在这种竞争格局中维持收入成长所面临的挑战更加复杂。

目录

第1章 全球癌症治疗药市场，简介

• 市场概要
• 调查范围
• 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

• 资料探勘
• 验证
• 一次采访
• 资料来源一览

第4章 全球癌症治疗药市场展望

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力分析
• 价值链分析

第5章 癌症治疗药的全球市场，癌症各类型

• 概要
• 血液癌症
• 肺癌症
• 乳癌
• 消化器官癌症
• 大肠癌症
• 妇产科癌症
• 前列腺癌症
• 其他

第6章 癌症治疗药的全球市场，疗法

• 概要
• 化疗
• 标靶治疗
• 免疫疗法
• 荷尔蒙疗法
• 其他

第7章 癌症治疗药的全球市场，各终端用户

• 概要
• 医院
• 专门诊所
• 癌症·放射治疗中心

第8章 癌症治疗药的全球市场，各地区

• 概要
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区
  • 南美
  • 中东·非洲

第9章 癌症治疗药的全球市场，竞争情形

• 概要
• 各公司的市场排行榜
• 主要的开发策略

第10章 企业简介

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Bayer AG

第11章 附录

• 相关调查

Cancer Therapeutics Market Valuation - 2024-2031

Significant milestones were achieved in the Cancer Therapeutics Market, with a value of USD 149.92 Billion attained in 2023. Various factors, including heightened research and development endeavors, greater collaboration among pharmaceutical entities, and amplified investments within the healthcare sector, fueled this achievement. The market is anticipated to witness a promising trajectory, with a projected CAGR of 14.6% during the forecast period from 2024 to 2031. By 2031, it is expected to soar to an impressive value of USD 491.41 Billion, reflecting the sustained momentum and evolving dynamics within the industry.

This growth is underpinned by factors such as the escalating prevalence of cancer globally, governmental initiatives promoting early detection, and the steady rise in cancer research endeavors, coupled with technological advancements, all contributing to the advancement of cancer therapeutics.

Cancer Therapeutics Market: Definition/Overview

Cancer therapeutics encompass treatments aimed at targeting alterations in cancer cells to impede tumor growth, including radiotherapy, chemotherapy, and surgery. The application of these therapies varies based on cancer type and stage, with ongoing research and clinical trials exploring treatments such as immunotherapy, targeted therapy, hormone therapy, and stem cell transplant. Market segmentation, based on cancer type and end users, is driven by the global rise in cancer prevalence, expected to double by 2031, particularly in Asia, Europe, and the Americas.

Market growth is further propelled by collaboration between pharmaceutical companies and increased research efforts. Market expansion is driven by government initiatives for cancer awareness and the demand for personalized medicine.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What Factors are Driving the Growth of the Cancer Therapeutics Market?

The demand for effective treatment options is propelled by the escalating prevalence of cancer globally, particularly in regions such as Asia, Europe, and the Americas. This rise in cancer cases necessitates advanced therapeutics, leading to market expansion. Innovation in cancer therapeutics is significantly contributed by heightened research and development endeavors within the field of oncology. Continuous exploration through studies and clinical trials facilitates the discovery of novel drugs and treatment modalities, thereby enriching the market with more effective solutions.

Moreover, innovation and the acceleration of cancer therapeutics development are fostered by collaborative efforts among pharmaceutical companies, research institutions, and various stakeholders. These partnerships facilitate resource pooling and knowledge sharing, resulting in more robust pipelines and the quicker introduction of new drugs to the market. Furthermore, market growth is bolstered by government initiatives aimed at raising cancer awareness, promoting early detection, and providing funding for research.

The expansion of treatment options available to cancer patients is driven by the growing demand for personalized medicine tailored to individual patient profiles, fueled by advances in genomic testing and technological innovations. This convergence of factors creates a favorable environment for the continuous progression and expansion of the Cancer Therapeutics Market.

What Factors are Plummeting Sales of Cancer Therapeutics Market?

The availability of generic versions due to patent expirations on blockbuster drugs intensifies competition and drives down prices for branded cancer therapeutics. This increased competition poses challenges for pharmaceutical companies, leading to reduced sales revenue. Also, easy accessibility to new cancer therapeutics is restricted by stringent regulatory requirements for drug approval and reimbursement, as well as pricing pressures from healthcare payers. Delays in regulatory approvals or changes in reimbursement policies further limit the adoption of cancer therapeutics, resulting in negative impact on sales.

The introduction of generic versions of branded cancer therapeutics, particularly for drugs losing patent protection, contributes to significant price erosion and decreased sales for originator companies. Treatment paradigms are also influenced by advances in cancer research, and shifting preferences of healthcare providers towards emerging therapies such as immunotherapy and targeted treatments. This shift may reduce the utilization of traditional chemotherapy, further impacting sales of conventional cancer therapeutics. Economic factors, including downturns, changes in healthcare spending, and fluctuations in reimbursement, as well as challenges related to treatment adherence and access issues, further compound the challenges faced by pharmaceutical companies in maintaining revenue growth in this competitive landscape.

Category-Wise Acumens

Which Therapy Type Category Holds the Dominant Market Share in the Cancer Therapeutics Market?

In the forecasted period, the targeted therapy segment is expected to demonstrate the highest Compound Annual Growth Rate (CAGR), attributed to its specificity toward cancer cells while minimizing toxicity to off-target cells. This category encompasses various therapeutic approaches, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules.

With cancer cells precisely targeted and healthy cells spared from harm, targeted therapy presents a promising avenue for more effective and tolerable cancer treatment options. Consequently, it contributes significantly to its dominance in the Cancer Therapeutics Market.

Will the Emergence of Cancer and Radiation Therapy Centres Drive Growth in the Cancer Therapeutics Market?

The growth of the Cancer Therapeutics Market is expected to be driven by the emergence of Cancer and Radiation Therapy Centres. It is anticipated that the largest market share will be held by the Cancer & Radiation Therapy Centre due to several factors. These centers are regarded as pivotal in the administration of cancer therapeutics, serving as hubs for a significant number of cancer treatments. Patients are often provided with a variety of treatments, including chemotherapy, radiotherapy, and targeted therapy, all of which contribute to the demand for cancer therapeutics.

Additionally, specialized equipment and expertise required for advanced treatment modalities are often housed within these centers, further driving the need for therapeutic interventions. Therefore, as Cancer and Radiation Therapy Centres continue to expand and cater to the increasing number of cancer patients, they are poised to play a central role in fueling the growth of the Cancer Therapeutics Market.

Could North America Drive an Increase in the Sales within the Cancer Therapeutics Market?

An increase in sales within the Cancer Therapeutics Market could be driven by North America. The region is positioned to dominate the market, primarily due to the widespread adoption of cancer therapeutics and significant funding provided by various organizations operating within the region. With advanced cancer treatment options being widely adopted and substantial financial support being provided by both public and private sectors in North America, the region is poised to stimulate growth in sales within the Cancer Therapeutics Market.

Furthermore, North America's leadership in the adoption of advanced cancer treatment options and its robust financial support from both public and private sectors contribute to its advantageous position. This favorable environment fosters a conducive landscape for the expansion of cancer therapeutics sales, positioning North America as a key driver of market growth.

Will the Sales of Cancer Therapeutics Market fare well in Asia Pacific?

The sales of the Cancer Therapeutics Market are expected to perform well in the Asia Pacific region. With high prevalence of cancer and increasing awareness about the importance of early detection and treatment, there is a significant growth in demand for cancer therapeutics in Asia Pacific. The region's potential for robust sales of cancer therapeutics is further enhanced by advancements in healthcare infrastructure and increasing investments in research and development activities. A surge in collaborations between pharmaceutical companies and healthcare institutions is being witnessed in this region, fostering innovation and the introduction of novel cancer treatment options, driving market growth.

The Government initiatives aimed at improving cancer care and access to treatment, along with the growing adoption of personalized medicine approaches, are expected to bolster the sales of cancer therapeutics in Asia Pacific. As healthcare systems in countries across the Asia Pacific continue to evolve and improve, there is a growing focus on addressing the unmet medical needs of cancer patients, presenting significant opportunities for market expansion in the region.

Competitive Landscape

Examining the competitive landscape of the Cancer Therapeutics Market is considered crucial for gaining insights into the industry's dynamics. This research aims to analyze the competitive landscape, focusing on key players, market trends, innovations, and strategies. By conducting this analysis, valuable insights will be provided to industry stakeholders, assisting them in effectively navigating the competitive environment and seizing emerging opportunities. Understanding the competitive landscape will enable stakeholders to make informed decisions, adapt to market trends, and develop strategies to enhance their market position and competitiveness in the Cancer Therapeutics Market.

Some of the prominent players operating in the Cancer Therapeutics Market include:

Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma Inc., Pfizer Inc., Novartis AG, Merck KGaA, Bayer AG, and Takeda Pharmaceutical Company Limited.

Latest Developments

In February 2024, Bristol-Myers Squibb attained FDA approval for OPDIVO (nivolumab) alongside Yervoy (ipilimumab) for the initial treatment of patients diagnosed with locally advanced or metastatic urothelial carcinoma (bladder cancer).

In February 2024, Merck & Co. revealed encouraging outcomes from a Phase 3 clinical trial of Keytruda (pembrolizumab) combined with chemotherapy as the primary therapy for advanced non-small cell lung cancer (NSCLC). The study exhibited a statistically significant enhancement in overall survival in comparison to chemotherapy alone.

In January 2024, Johnson & Johnson's Janssen unit disclosed favorable findings from a Phase 3 trial of Darzalex (daratumumab) combined with bortezomib and lenalidomide for managing patients with newly diagnosed multiple myeloma. The study highlighted a statistically significant advancement in progression-free survival when contrasted with the administration of lenalidomide and bortezomib alone.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL CANCER THERAPEUTICS MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL CANCER THERAPEUTICS MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL CANCER THERAPEUTICS MARKET, BY CANCER TYPE

• 5.1. Overview
• 5.2. Blood Cancer
• 5.3. Lung Cancer
• 5.4. Breast Cancer
• 5.5. Gastrointestinal Cancer
• 5.6. Colorectal Cancer
• 5.7. Gynecologic Cancer
• 5.8. Prostate Cancer
• 5.9. Others

6. GLOBAL CANCER THERAPEUTICS MARKET, BY THERAPY

• 6.1. Overview
• 6.2. Chemotherapy
• 6.3. Targeted Therapy
• 6.4. Immunotherapy
• 6.5. Hormonal Therapy
• 6.6. Others

7. GLOBAL CANCER THERAPEUTICS MARKET, BY END USERS

• 7.1. Overview
• 7.2. Hospitals
• 7.3. Specialty Clinics
• 7.4. Cancer and Radiation Therapy Centres

8. GLOBAL CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

• 8.1. Overview
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. U.K.
  • 8.3.3. France
  • 8.3.4. Rest of Europe
• 8.4. Asia Pacific
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Rest of Asia Pacific
• 8.5. Rest of the World
  • 8.5.1. Latin America
  • 8.5.2. Middle East & Africa

9. GLOBAL CANCER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

• 9.1. Overview
• 9.2. Company Market Ranking
• 9.3. Key Development Strategies

10. COMPANY PROFILES

• 10.1. F. Hoffmann-La Roche AG
  • 10.1.1. Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Outlook
  • 10.1.4. Key Developments
• 10.2. Bristol-Myers Squibb Company
  • 10.2.1. Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Outlook
  • 10.2.4. Key Developments
• 10.3. AbbVie, Inc.
  • 10.3.1. Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Outlook
  • 10.3.4. Key Developments
• 10.4. Johnson & Johnson
  • 10.4.1. Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Outlook
  • 10.4.4. Key Developments
• 10.5. Celgene Corporation
  • 10.5.1. Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Outlook
  • 10.5.4. Key Developments
• 10.6. Astellas Pharma Inc.
  • 10.6.1. Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Outlook
  • 10.6.4. Key Developments
• 10.7. Pfizer, Inc.
  • 10.7.1. Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Outlook
  • 10.7.4. Key Developments
• 10.8. Novartis AG
  • 10.8.1. Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Outlook
  • 10.8.4. Key Developments
• 10.9. Merck KGaA
  • 10.9.1. Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Outlook
  • 10.9.4. Key Developments
• 10.10. Bayer AG
  • 10.10.1. Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Outlook
  • 10.10.4. Key Developments

11. Appendix

• 11.1. Related Research